P535: UPDATES FROM ITALIAN MULTICENTER REAL-LIFE EXPERIENCE ON CPX-351 THERAPY IN YOUNG PATIENTS (<60 YEARS OLD).

Míreanna comhchosúla

• Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia
  de réir: Calogero Vetro, et al.
  Foilsithe / Cruthaithe: (2025-12-01)
• Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy
  de réir: Salvatore Perrone, et al.
  Foilsithe / Cruthaithe: (2026-02-01)
• Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
  de réir: Thomas Cluzeau, et al.
  Foilsithe / Cruthaithe: (2025-02-01)
• Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy
  de réir: Raffaele Palmieri, et al.
  Foilsithe / Cruthaithe: (2024-02-01)
• P530: CPX-351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION
  de réir: Carola Riva, et al.
  Foilsithe / Cruthaithe: (2023-08-01)